Linda M O'Keeffe1, Anna Ramond2, Clare Oliver-Williams3, Peter Willeit4, Ellie Paige5, Patrick Trotter6, Jonathan Evans3, Jonas Wadström7, Michael Nicholson6, Dave Collett8, Emanuele Di Angelantonio9. 1. University of Bristol, Bristol, United Kingdom (L.M.O.). 2. University of Cambridge and National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, Cambridge, United Kingdom (A.R.). 3. University of Cambridge, Cambridge, United Kingdom (C.O., J.E.). 4. University of Cambridge, Cambridge, United Kingdom, and Medical University of Innsbruck, Innsbruck, Austria (P.W.). 5. University of Cambridge, Cambridge, United Kingdom, and Australian National University, Canberra, Australia (E.P.). 6. National Institute for Health Research Blood and Transplant Research Unit in Organ Donation and Transplantation and University of Cambridge, Cambridge, United Kingdom (P.T., M.N.). 7. Karolinska University Hospital, Stockholm, Sweden (J.W.). 8. National Health Service Blood and Transplant, Bristol, United Kingdom (D.C.). 9. University of Cambridge, National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, and National Health Service Blood and Transplant, Cambridge, United Kingdom (E.D.).
Abstract
Background: Long-term health risks for adults who donate kidneys are unclear. Purpose: To summarize evidence about mid- and long-term health risks associated with living kidney donation in adults. Data Sources: PubMed, Embase, Scopus, and PsycINFO without language restriction from April 1964 to July 2017. Study Selection: Observational studies with at least 1 year of follow-up that compared health outcomes in adult living kidney donors versus nondonor populations. Data Extraction: Two investigators independently extracted study data and assessed study quality. Data Synthesis: 52 studies, comprising 118 426 living kidney donors and 117 656 nondonors, were included. Average follow-up was 1 to 24 years. No evidence suggested higher risk for all-cause mortality, cardiovascular disease, hypertension, type 2 diabetes, or adverse psychosocial health outcomes in living kidney donors than in nondonor populations. Donors had higher diastolic blood pressure, lower estimated glomerular filtration rates, and higher risk for end-stage renal disease (ESRD) (relative risk [RR], 8.83 [95% CI, 1.02 to 20.93]) and preeclampsia in female donors (RR, 2.12 [CI, 1.06 to 4.27]). Despite the increased RR, donors had low absolute risk for ESRD (incidence rate, 0.5 event [CI, 0.1 to 4.9 events] per 1000 person-years) and preeclampsia (incidence rate, 5.9 events [CI, 2.9 to 8.9 events] per 100 pregnancies). Limitation: Generalizability was limited by selected control populations, few studies reported pregnancy-related outcomes, and few studies were from low- and middle-income countries. Conclusion: Although living kidney donation is associated with higher RRs for ESRD and preeclampsia, the absolute risk for these outcomes remains low. Compared with nondonor populations, living kidney donors have no increased risk for other major chronic diseases, such as type 2 diabetes, or for adverse psychosocial outcomes. Primary Funding Source: National Health Service Blood and Transplant and National Institute for Health Research. (PROSPERO: CRD42017072284).
Background: Long-term health risks for adults who donate kidneys are unclear. Purpose: To summarize evidence about mid- and long-term health risks associated with living kidney donation in adults. Data Sources: PubMed, Embase, Scopus, and PsycINFO without language restriction from April 1964 to July 2017. Study Selection: Observational studies with at least 1 year of follow-up that compared health outcomes in adult living kidney donors versus nondonor populations. Data Extraction: Two investigators independently extracted study data and assessed study quality. Data Synthesis: 52 studies, comprising 118 426 living kidney donors and 117 656 nondonors, were included. Average follow-up was 1 to 24 years. No evidence suggested higher risk for all-cause mortality, cardiovascular disease, hypertension, type 2 diabetes, or adverse psychosocial health outcomes in living kidney donors than in nondonor populations. Donors had higher diastolic blood pressure, lower estimated glomerular filtration rates, and higher risk for end-stage renal disease (ESRD) (relative risk [RR], 8.83 [95% CI, 1.02 to 20.93]) and preeclampsia in female donors (RR, 2.12 [CI, 1.06 to 4.27]). Despite the increased RR, donors had low absolute risk for ESRD (incidence rate, 0.5 event [CI, 0.1 to 4.9 events] per 1000 person-years) and preeclampsia (incidence rate, 5.9 events [CI, 2.9 to 8.9 events] per 100 pregnancies). Limitation: Generalizability was limited by selected control populations, few studies reported pregnancy-related outcomes, and few studies were from low- and middle-income countries. Conclusion: Although living kidney donation is associated with higher RRs for ESRD and preeclampsia, the absolute risk for these outcomes remains low. Compared with nondonor populations, living kidney donors have no increased risk for other major chronic diseases, such as type 2 diabetes, or for adverse psychosocial outcomes. Primary Funding Source: National Health Service Blood and Transplant and National Institute for Health Research. (PROSPERO: CRD42017072284).
Authors: Frank McCormick; Philip J Held; Glenn M Chertow; Thomas G Peters; John P Roberts Journal: J Am Soc Nephrol Date: 2019-07-25 Impact factor: 10.121
Authors: Amit X Garg; Andrew S Levey; Bertram L Kasiske; Michael Cheung; Krista L Lentine Journal: Clin J Am Soc Nephrol Date: 2020-04-10 Impact factor: 8.237
Authors: Otto A Sanchez; Laine K Ferrara; Sarah Rein; Danielle Berglund; Arthur J Matas; Hassan N Ibrahim Journal: Am J Transplant Date: 2018-04-06 Impact factor: 8.086
Authors: Tarak Srivastava; Daniel P Heruth; R Scott Duncan; Mohammad H Rezaiekhaligh; Robert E Garola; Lakshmi Priya; Jianping Zhou; Varun C Boinpelly; Jan Novak; Mohammed Farhan Ali; Trupti Joshi; Uri S Alon; Yuexu Jiang; Ellen T McCarthy; Virginia J Savin; Ram Sharma; Mark L Johnson; Mukut Sharma Journal: Cells Date: 2021-05-19 Impact factor: 7.666